Nanotized curcumin‐benzothiophene conjugate: A potential combination for treatment of cerebral malaria. Issue 12 (9th October 2020)

• Record Type: Journal Article
• Authors: Ghosh, Aparajita; Banerjee, Tanushree
• Is Part Of: IUBMB life. Volume 72:Issue 12(2020)
• Page Start: 2637
• Page End: 2650
• Publication Date: 2020-10-09
• Subjects: benzothiophene compound 6 -- bioavailability -- curcumin -- dispersibility -- malaria -- nanotized conjugate; Biochemistry -- Periodicals; Molecular biology -- Periodicals; 572.8
• DOI: 10.1002/iub.2394
• Languages: English
• ISSNs: 1521-6543

Abstract

Abstract: The declining effectiveness of the available antimalarial drugs due to drug resistance requires a continued effort to develop new therapeutic approaches. In this context, combination therapies hold a great promise for developing effective first‐line antimalarial treatments for reducing malaria mortality. The present study explores the antimalarial efficacy of nanotized formulation of curcumin in combination with benzothiophene compound 6 (3‐bromo‐ N ‐(4‐fluorobenzyl)‐benzo[b]thiophene‐2‐carboxamide) with a view to achieve better efficacy at a very low dose in comparison to that accomplished with monotherapy alone. Herein, we formulated nanotized conjugate of curcumin and compound 6 (cur‐compound 6) in the size range of 30–90 nm as observed via TEM, AFM and DLS analysis in the study. The nanotized preparation was found to be readily dispersible in water, physically and chemically stable and exhibited sustained release profile of both curcumin and compound 6 till 48 hr. Treatment of P. falciparum parasites with the nanotized conjugate for 24 hr resulted in rapid clearance of the parasites. Furthermore, P. berghei infected mice treated with nanotized conjugate formulation survived till 90 days with complete eradication of the parasites from RBC. This improved efficacy of the nanotized formulation was possible because of the increased absorption of the compounds via oral administration owing to enhanced dispersibility of the formulation in aqueous medium. Moreover, an improved oral bioavailability of the nanotized formulation lowered the dosage at which the pharmacological effect was achieved while avoiding any observable adverse harmful side effects.